Vimseltinib Approved for Symptomatic Tendon Sheath Giant Cell Tumor (TGCT)
The U.S. Food and Drug Administration (FDA) has approved Deciphera Pharmaceuticals’ vimseltinib/Romvimza for the treatment of adult patients with symptomatic tendon sheath giant cell tumor (TGCT) who are not candidates for surgical removal of the tumor and who have a potential for worsening functional limitations or severe complications.
TGCT is a nonmalignant tumor that develops in the synovial membrane, bursa, and tendons. The primary treatment for this disease is surgery.
){kind=link}